The Canadian Press - ONLINE EDITION

Pfizer raises AztraZeneca offer for 3rd time highlighting flurry of drug industry deals

  • Print

U.S. drugmaker Pfizer has raised its takeover bid for British rival AstraZeneca for a third time, hiking the stock-and-cash offer to nearly $119 billion (70.7 billion pounds). The move is the latest in a flurry of proposed drug takeovers this year. The deals highlight how the global pharmaceutical industry could over time consolidate into a very small number of massive companies as competition increases from generic versions of medicines. The enhanced economies of scale could boost returns for shareholders but what it means for consumers is still unclear.

— PFIZER-ASTRAZENECA

Pfizer Inc., the world's second-biggest drugmaker by revenue, has been courting No. 8 AstraZeneca PLC since January, saying their businesses are complementary and would be stronger together. AstraZeneca has repeatedly rejected Pfizer's offers, insisting they significantly undervalue the company and its experimental drugs. The company and British government officials also have raised concerns about the prospect of job cuts, facility closures and the U.K. losing some of its science leadership.

— BAYER-MERCK

Germany's Bayer AG, which invented aspirin more than a century ago, announced a $14.2 billion deal in May to buy Merck's consumer health business. The deal would make Bayer No. 1 worldwide in skin and gastrointestinal products, No. 2 in the huge cold and allergy category, and No. 3 in pain relievers. For Merck & Co., it's an opportunity to shed a slow-growing business it inherited in 2009 when it bought Schering-Plough Corp. to get its experimental prescription medicines. The deal still needs regulatory approval.

— NOVARTIS-GLAXOSMITHKLINE

In April, Switzerland's Novartis AG agreed to buy GlaxoSmithKline's cancer-drug business for up to $16 billion, to sell most of its vaccines business to GSK for $7.1 billion, plus royalties, and to sell its animal health division to Eli Lilly and Co. of Indianapolis for about $5.4 billion. The deals are likely to be completed in the first half of 2015.

— VALEANT-ALLERGAN

Canada's Valeant Pharmaceuticals has made an unsolicited offer of nearly $46 billion for Botox maker Allergan Inc., which has turned it down, so far. Allergan, which also makes the dry eye treatment Restasis, says its growth prospects are stronger as a separate company.

Fact Check

Fact Check

Have you found an error, or know of something we’ve missed in one of our stories?
Please use the form below and let us know.

* Required
  • Please post the headline of the story or the title of the video with the error.

  • Please post exactly what was wrong with the story.

  • Please indicate your source for the correct information.

  • Yes

    No

  • This will only be used to contact you if we have a question about your submission, it will not be used to identify you or be published.

  • Cancel

Having problems with the form?

Contact Us Directly
  • Print

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is be a Winnipeg Free Press print or e-edition subscriber to join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

Have Your Say

Comments are open to Winnipeg Free Press print or e-edition subscribers only. why?

Have Your Say

Comments are open to Winnipeg Free Press Subscribers only. why?

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Peguis Chief Hudson comments on toddler's death upgrade to homicide investigation

View more like this

Photo Store Gallery

  • A young gosling prepares to eat dandelions on King Edward St Thursday morning-See Bryksa 30 Day goose challenge- Day 17- bonus - May 24, 2012   (JOE BRYKSA / WINNIPEG FREE PRESS)
  • A nesting goose sits on the roof of GoodLife Fitness at 143 Nature Way near Kenaston as the morning sun comes up Wednesday morning- See Bryksa’s Goose a Day Photo- Day 07- Web crop-May 09, 2012   (JOE BRYKSA / WINNIPEG FREE PRESS)

View More Gallery Photos

Poll

Should the city grant mosquito buffer zones for medical reasons only?

View Results

View Related Story

Ads by Google